Mirador Therapeutics Begins First-in-Human Testing of MT-251, a Bispecific Antibody Targeting TL1A and IL-23
Mirador Therapeutics has initiated dosing in a Phase 1 MT-251 clinical trial evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of its bispecific antibody in healthy volunteers. The study, registered as NCT07423299 and currently recruiting at a single site in San Diego, California, marks the second biologic from the company's pipeline to enter human testing within the span of a few months. MT-251 is designed to simultaneously neutralize two cytokines, TL1A and IL-23, that operate through distinct but convergent inflammatory pathways. If the molecule's dual-targeting architecture translates into a tolerable safety profile in this MT-251 first-in-human study, it could eventually be directed toward immune-mediated inflammatory and fibrotic diseases, a therapeutic space where Mirador Therapeutics has staked its corporate identity.
The trial is randomized, double-blind, and placebo-controlled, structured in two sequential parts. Part 1 enrolls participants into single ascending dose cohorts administered intravenously or subcutaneously. Part 2 follows with multiple ascending dose cohorts using the same routes. Across both parts, approximately 70 healthy adults between the ages of 19 and 55 are expected to participate. The primary endpoint is the incidence of adverse events and serious adverse events, assessed up to 14 days after each dose, including clinically relevant changes in laboratory values, electrocardiograms, vital signs, and physical examinations. The trial began enrolling in Q1 2026, with an estimated primary completion date of Q1 2027.
What MT-251 Is and Why It Exists
MT-251 is a long-acting humanized bispecific antibody engineered to bind and neutralize both TL1A (also known as TNFSF15) and IL-23. The molecule reportedly incorporates pH-sensitive binding and FcRn-mediated IgG recycling to extend its serum half-life, a design feature that could enable less frequent dosing in eventual patient studies.
The biological rationale for dual blockade rests on the distinct but overlapping roles these two cytokines play in intestinal and systemic inflammation. TL1A signals through DR3 (TNFRSF25), driving Th1 and Th17 polarization, activating innate lymphoid cells, and promoting tissue fibrosis. Genetic variants in the TNFSF15 locus are among the most consistently replicated risk alleles for inflammatory bowel disease. IL-23, a heterodimer of p19 and p40 subunits, acts through the IL-23 receptor to sustain pathogenic Th17 cell populations and is already a validated therapeutic target in Crohn's disease and ulcerative colitis, as demonstrated by approved agents such as risankizumab, guselkumab, and mirikizumab.
Preclinical work attributed to Mirador-affiliated investigators, presented at the American College of Rheumatology meeting, described the engineering of a humanized anti-TL1A antibody with extended half-life properties and concluded that development of a bispecific antibody targeting TL1A alongside an orthogonal inflammatory pathway was warranted. MT-251 appears to be the realization of that stated objective.
The MT-251 Phase 1 Study in Detail
The trial design reflects standard practice for first-in-human biologic evaluation. Eligibility is restricted to healthy adults in good general health. Female participants must be of non-childbearing potential, defined as postmenopausal or surgically sterile with documentation predating enrollment by at least six months. Male participants are required to use barrier contraception. Exclusion criteria rule out individuals with clinically relevant organ disease, abnormal laboratory or ECG findings, recent use of prescription or investigational drugs, and any history of substance abuse within 24 months. The study uses triple masking, blinding participants, investigators, and an unspecified third party.
No secondary endpoints are listed in the registry entry, and no data monitoring committee has been established. The absence of a DMC is not unusual for a healthy-volunteer dose-escalation study where the risk profile is expected to be low at starting doses, though it does mean that dose-escalation decisions will rest with the sponsor and investigators using predefined stopping rules rather than an independent body.
The trial is being conducted at a single facility, the Mirador Clinical Department in San Diego (ZIP 92121), with a toll-free contact line and a dedicated email address at [email protected]. No collaborators are listed.
Mirador Therapeutics Pipeline and Corporate Context
Mirador Therapeutics was founded in 2024 with over $400 million in Series A financing led by ARCH Venture Partners. The company has described its platform as integrating multi-omics datasets, spanning genomics, transcriptomics, proteomics, and clinical data, to identify and prioritize targets in immune-mediated diseases. Its stated focus areas include inflammatory bowel disease and related inflammatory and fibrotic conditions.
The Mirador Therapeutics pipeline includes at least three clinical-stage or near-clinical assets. MT-501 is an oral small molecule in a Phase 1/Phase 2 platform trial (ASCEND-IBD) for inflammatory bowel disease. MT-201 is another biologic in first-in-human testing (NCT07219368), though its target has not been publicly disclosed. MT-251 is the third asset to enter human studies, and the first for which the bispecific TL1A/IL-23 mechanism has been described in external presentations. The "MT-2XX" designation series appears to denote the company's biologic programs, while "MT-5XX" may correspond to small molecules, though this naming convention has not been formally confirmed.